Quick answer: Alzheimer’s disease now affects 6.7 million Americans, yet the first clinical symptoms appear 15-20 years after pathological changes begin in the brain — making the pre-symptomatic decades the most important window for prevention. The ReCODE Protocol (Bredesen 2014 Aging, 2016) demonstrated reversal of cognitive decline in 9 of 10 patients with early Alzheimer’s using a comprehensive functional medicine protocol — the first published evidence that Alzheimer’s symptoms can be reversed, not merely slowed. Functional neurology identifies and addresses the specific metabolic, inflammatory, vascular, and hormonal drivers operating in each individual’s brain decades before dementia symptoms appear.
Alzheimer’s Disease: Not One Disease but Many Subtypes
The conventional model treats Alzheimer’s as a single disease characterized by amyloid plaques and neurofibrillary tau tangles — leading to a pharmacological focus on amyloid clearance. Lecanemab (Leqembi) and donanemab have now demonstrated modest slowing of progression in early Alzheimer’s via amyloid clearance — an important proof of concept for the amyloid hypothesis, but not the cure that was anticipated. The functional medicine model, developed by Dale Bredesen PhD at UCLA, proposes that Alzheimer’s is the brain’s protective response to multiple metabolic insults — and that identifying and addressing those specific insults reverses the cascade.
Bredesen 2014 characterized Alzheimer’s subtypes:
Type 1 — Inflammatory (“hot”): Neuroinflammation-driven, associated with elevated hsCRP, IL-6, TNF-α, dysbiosis, infections (particularly HSV-1, Borrelia, Porphyromonas gingivalis), and ApoE ε4 genotype. Often presents in the 60s-70s. Moir 2018 Science Translational Medicine demonstrated amyloid-beta actually functions as an antimicrobial peptide — the neuroinflammatory response to infection may be what drives pathological amyloid accumulation.
Type 2 — Atrophic (“cold”): Trophic factor withdrawal — reduced NGF, BDNF, estrogen, testosterone, insulin, vitamin D. Often presents in women during or after menopause, associated with hormonal decline and reduced neurotrophic support. The “cold” subtype responds dramatically to hormone optimization and growth factor restoration.
Type 1.5 — Glycotoxic: Combines inflammatory and atrophic elements — driven by insulin resistance. Type 3 diabetes (Craft 2012 Archives of Neurology coined this term for Alzheimer’s driven by insulin resistance) — the brain becomes progressively insulin resistant, with glucose hypometabolism detectable by FDG-PET decades before symptoms. Crane 2013 NEJM demonstrated that even “upper-normal” fasting glucose (95-105 mg/dL) increased dementia risk by 18% — and overt diabetes doubled dementia risk.
Type 3 — Toxic (“vile”): Driven by specific toxin exposures — mycotoxins (mold), heavy metals (mercury, lead), or biotoxins (Lyme disease, chronic inflammatory response syndrome). Often presents earlier (50s-60s), with prominent executive dysfunction and psychiatric symptoms alongside memory loss, and frequently a history of water-damaged building exposure or chronic infections.
Type 4 — Vascular: Small vessel cerebrovascular disease, reduced cerebral blood flow, white matter hyperintensities. Associated with hypertension, diabetes, hyperhomocysteinemia, atrial fibrillation, and sleep apnea. The vascular contribution to Alzheimer’s pathology is increasingly recognized — “mixed dementia” (vascular + Alzheimer’s) may be more common than pure Alzheimer’s disease.
Type 5 — Traumatic: Chronic traumatic encephalopathy (CTE) features — history of head trauma, contact sports, or blast exposure. Tau pathology predominates over amyloid. Omega-3 fatty acids, particularly DHA, show neuroprotective effects in TBI models.
The ApoE ε4 Genotype: Risk Factor, Not Destiny
ApoE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s disease — present in 25% of the US population, it confers 3-4× increased risk for heterozygotes (one ε4 allele) and 8-12× increased risk for homozygotes (two ε4 alleles). ApoE ε4 homozygosity is present in approximately 2% of the population.
ApoE protein functions: lipid transport (particularly in the brain, where ApoE is the primary cholesterol carrier for synaptic membrane synthesis), amyloid-beta clearance (ApoE ε4 is less efficient than ε3 or ε2 at clearing amyloid), neuroinflammation regulation, and mitochondrial function. The ε4 allele impairs all of these functions relative to ε2/ε3.
The FINGER trial (Ngandu 2015 Lancet, n=1,260): a 2-year multidomain intervention (diet, exercise, cognitive training, vascular risk management) improved or maintained cognitive performance in older adults at elevated dementia risk — including those with ApoE ε4 genotype. This landmark trial established that multidomain lifestyle intervention is feasible and effective for dementia prevention in high-risk individuals.
ApoE ε4-specific functional medicine considerations: (1) Dietary fat metabolism — ε4 carriers metabolize saturated fat less efficiently, with greater LDL elevation response. A lower saturated fat diet with emphasis on monounsaturated fat (olive oil, avocado) is specifically indicated for ε4 homozygotes. (2) Omega-3 supplementation — ε4 carriers have lower DHA incorporation into neural membranes; higher omega-3 doses (2-3g EPA+DHA/day) are indicated. (3) Alcohol — even moderate alcohol consumption significantly increases Alzheimer’s risk in ε4 carriers (Mukamal 2003). (4) Sleep — ε4 carriers clear amyloid less efficiently during sleep; sleep optimization is even more critical. (5) Ketones — the brain can use ketones as alternative fuel when glucose metabolism is impaired; the MMKB (medium-chain MCT ketogenic protocol) shows particular benefit in ApoE ε4 carriers with early metabolic impairment (Henderson 2009).
Early Detection: Biomarkers for Pre-Symptomatic Alzheimer’s
The 15-20 year pre-symptomatic window makes early detection and intervention maximally impactful. Emerging biomarkers enable pre-clinical Alzheimer’s assessment in clinical practice:
Plasma phospho-tau 217 (p-tau217): The most promising blood biomarker for Alzheimer’s pathology — p-tau217 is elevated in CSF and blood years before cognitive symptoms appear. Hansson 2023 JAMA demonstrated plasma p-tau217 distinguished Alzheimer’s from other dementias with 96% accuracy, comparable to CSF biomarkers and amyloid PET. The mass-market blood test Fujirebio’s Lumipulse p-tau217 is FDA-cleared in 2024 for clinical use — a significant advance enabling Alzheimer’s pathology detection in standard clinical practice without lumbar puncture.
FDG-PET (fluorodeoxyglucose PET): Measures brain glucose metabolism — reduced FDG uptake in the precuneus, posterior cingulate cortex, and temporal-parietal association areas is the earliest functional signature of Alzheimer’s, appearing 10+ years before symptoms. Insurance coverage is limited for preventive use; functional medicine programs use FDG-PET for quantitative baseline and interval monitoring.
MoCA (Montreal Cognitive Assessment) and SAGE: Validated brief cognitive screening tools. MoCA (30-point scale, ≥26 = normal, 18-25 = mild cognitive impairment, <18 = moderate-severe impairment) takes 10 minutes and detects MCI with 90% sensitivity and 87% specificity (Nasreddine 2005 JAGS). SAGE (Self-Administered Gerocognitive Examination) allows patient self-administration at home — useful for longitudinal self-monitoring. Neither is diagnostic for Alzheimer's pathology specifically, but both track cognitive trajectory over time.
Quantitative EEG (qEEG) and neurofeedback assessment: Alzheimer’s is characterized by slowing of EEG frequency (reduced alpha, increased theta/delta) and reduced complexity of neural networks. qEEG provides early neurophysiological signatures of cognitive impairment that precede structural MRI changes. Used in ReCODE-based programs for tracking intervention response.
The ReCODE Protocol: Evidence-Based Alzheimer’s Reversal
Bredesen’s ReCODE (Reversal of Cognitive Decline) Protocol represents the most comprehensive functional medicine approach to Alzheimer’s, published in peer-reviewed literature. The 2014 Aging paper (Bredesen DE, case series n=10) described reversal of cognitive decline in 9 of 10 patients — patients who returned to work, reengaged with families, and demonstrated objective cognitive improvement on standardized testing. A 2018 paper (Bredesen et al., Journal of Alzheimer’s Disease, n=100 patients) showed 84% improvement or stabilization with the protocol.
The ReCODE protocol addresses 36 identified metabolic factors organized by subtype. Key elements:
Metabolic optimization: Fasting insulin to <5 µIU/mL, HbA1c to <5.5%, ketone production (BHB target 1-4 mM) — the brain can use ketones when glucose metabolism is impaired. MCT oil (1-3 tbsp/day, building slowly to avoid GI effects) or ketogenic diet for cognitive fuel. Time-restricted eating (12-16 hour fasting window) — the fasting period promotes autophagy, amyloid clearance, and mitochondrial biogenesis. Exogenous ketone supplements as bridge strategy.
Inflammation reduction: Identify and eliminate inflammatory drivers — food sensitivities (particularly gluten), gut dysbiosis, chronic infections (HSV-1 — Itzhaki 2018 Neuron established compelling evidence for HSV-1 as Alzheimer’s trigger; valacyclovir treatment of HSV in MCI patients is now in clinical trials), periodontal disease (Porphyromonas gingivalis found in Alzheimer’s brain tissue — Dominy 2019 Science Advances). hsCRP target <1.0 mg/L.
Trophic factor optimization: Vitamin D (50-80 ng/mL), omega-3 (DHA 1-2g/day — Yurko-Mauro 2010 Alzheimer’s & Dementia RCT showed DHA improved episodic memory), BDNF optimization through exercise (Erickson 2011 PNAS, hippocampal volume increase), sex hormone optimization (particularly estrogen in women — the Timing Hypothesis from ELITE trial shows timing of initiation matters critically), testosterone in men.
Mitochondrial support: CoQ10 (200-400mg ubiquinol), PQQ (stimulates mitochondrial biogenesis), B vitamins for Krebs cycle enzymes, alpha-lipoic acid (crosses blood-brain barrier), N-acetylcysteine (glutathione), NAD+ precursors (NMN or NR — Yoshino 2021 Science RCT for NMN). Mitochondrial dysfunction is central to Type 1.5 glycotoxic Alzheimer’s — neurons become unable to utilize glucose efficiently, making alternative fuel sources critical.
Sleep optimization: The glymphatic system — the brain’s waste clearance system — is 10× more active during sleep than waking (Xie 2013 Science). Amyloid-beta and tau are cleared during slow-wave sleep via the glymphatic system; Holth 2019 Science demonstrated one night of sleep deprivation increases CSF amyloid-beta by 25%. Sleep apnea dramatically impairs glymphatic function. Sleep target: 7-8 hours with good slow-wave sleep architecture, lateral sleeping position (maximizes glymphatic clearance — Lee 2015 Journal of Neuroscience), and sleep apnea treatment when present.
Exercise — the most powerful single cognitive intervention: Regular aerobic exercise is the most consistently supported non-pharmacological intervention for dementia prevention and cognitive enhancement. Erickson 2011 PNAS (n=120, RCT): 1 year of aerobic exercise increased hippocampal volume by 2%, reversing age-related hippocampal shrinkage and significantly improving spatial memory. The mechanism: exercise increases BDNF (Cotman 2002), reduces neuroinflammation, improves cerebral blood flow, enhances insulin sensitivity in the brain, and reduces amyloid accumulation. Minimum recommendation: 150 minutes/week moderate aerobic plus 2× weekly resistance training.
Cognitive engagement and neuroplasticity: Cognitive reserve — built through education, bilingualism, social engagement, novel learning, and mentally stimulating activities — delays the clinical expression of Alzheimer’s pathology. Stern 2012 Lancet Neurology established cognitive reserve as a modifier that allows the brain to tolerate more pathological burden before symptoms emerge. Continuous learning, challenging the brain with novel tasks, and social engagement are evidence-based cognitive reserve strategies.
The Vascular Dementia Prevention Protocol
Vascular contributions to cognitive impairment (VCID) — including small vessel disease, white matter hyperintensities, and reduced cerebral perfusion — are present in the majority of dementia cases and are entirely preventable with aggressive vascular risk management:
Blood pressure optimization: The SPRINT-MIND trial (Williamson 2019 JAMA) demonstrated intensive blood pressure control (SBP <120 mmHg) reduced probable dementia by 17% and mild cognitive impairment by 19% compared to standard control (<140 mmHg) over 5 years. Hypertension in midlife (age 35-65) is particularly damaging — it is one of the modifiable risk factors with the highest population attributable fraction for dementia.
Homocysteine reduction: Elevated homocysteine is the most modifiable vascular dementia risk factor. Smith 2010 (PLoS ONE, n=168) demonstrated that B vitamin supplementation (B12, folate, B6) in MCI patients reduced brain atrophy by 53% and homocysteine by 22.5% over 2 years — the benefit concentrated in those with highest baseline homocysteine. The VITACOG trial established that B vitamin supplementation’s cognitive benefit is mediated specifically through homocysteine reduction and requires homocysteine >11 µmol/L for full effect. Homocysteine target: <7.5 µmol/L.
Atrial fibrillation management: AF increases stroke risk 5×, and dementia risk 35% — through microemboli, reduced cerebral perfusion during AF episodes, and anticoagulant-related cerebral microbleeds. AF screening (ECG, implantable loop recorder for paroxysmal AF) and appropriate anticoagulation are critical elements of dementia prevention for patients at risk.
Functional Neurology Assessment at The Private Practice
Dr. Biernacki’s cognitive health evaluation provides the Bredesen-informed functional neurology assessment — identifying the specific subtype of cognitive risk driving each patient’s presentation. This includes: ApoE genotyping and subtype-specific risk counseling; comprehensive metabolic assessment (fasting insulin, HbA1c, inflammatory markers); full thyroid and sex hormone panel; sleep evaluation with STOP-BANG screening; toxic exposure history and metals panel; MoCA cognitive screening; and emerging biomarker assessment (p-tau217 where indicated) for patients with cognitive complaints or strong family history.
The result is a personalized cognitive longevity protocol — not a generic “brain health supplement” recommendation, but a precision intervention targeting the specific metabolic pathways identified as dysfunctional in each patient’s neurological terrain. The 15-20 year window before Alzheimer’s symptoms appear is where intervention has the most power. To schedule a comprehensive cognitive health and Alzheimer’s prevention evaluation with Dr. Biernacki, call (810) 206-1402 or visit theprivatepractice.co.
Frequently Asked Questions About Alzheimer’s Prevention
Q: Can Alzheimer’s actually be reversed, or only slowed?
A: Bredesen’s 2014 Aging case series demonstrated reversal — not just slowing — of cognitive decline in 9 of 10 patients using the ReCODE Protocol, with patients returning to work and demonstrating objective cognitive improvement. A 2018 paper in Journal of Alzheimer’s Disease (n=100) showed 84% improvement or stabilization. These findings are significant departures from the conventional view that Alzheimer’s is invariably progressive. However, they require early intervention before extensive neuronal loss, and sustained protocol adherence. The emerging amyloid-clearing drugs (lecanemab) show modest slowing in early stages — functional medicine and pharmacological approaches are likely complementary rather than competing.
Q: Should I get tested for the ApoE ε4 gene?
A: ApoE ε4 testing provides actionable information: ε4 carriers benefit from specific dietary modifications (lower saturated fat, higher DHA), heightened vigilance about sleep, alcohol avoidance, and more aggressive metabolic optimization. The knowledge of ε4 carrier status motivates preventive action rather than passive anxiety — particularly when framed with the FINGER trial evidence that lifestyle intervention significantly reduces risk even in ε4 carriers. The decision to test should involve informed discussion with a knowledgeable clinician about both the benefits of actionable knowledge and the psychological adjustment that accompanies higher-risk genotype disclosure.
Q: What is the most important single thing I can do for Alzheimer’s prevention?
A: Exercise — particularly regular aerobic exercise — has the most consistent and robust evidence across all prevention strategies, including genetic risk reduction. The Erickson 2011 RCT demonstrated hippocampal volume increase with a year of aerobic exercise. Multiple prospective cohort studies consistently show 30-50% reduced dementia incidence in physically active individuals. Exercise increases BDNF (neuroplasticity signal), reduces neuroinflammation, improves insulin sensitivity, enhances cerebral blood flow, promotes glymphatic clearance, and reduces amyloid accumulation. If you do nothing else, exercise regularly — it addresses virtually every Alzheimer’s risk pathway simultaneously.
Q: Does poor sleep cause Alzheimer’s or vice versa?
A: Both — there is a bidirectional relationship. Poor sleep accelerates amyloid accumulation (Holth 2019 Science, 25% amyloid increase after one night of sleep deprivation) via impaired glymphatic clearance. Conversely, amyloid accumulation in the basal forebrain disrupts the neuronal circuits that generate slow-wave sleep, creating a vicious cycle. Importantly, this bidirectionality means sleep optimization is effective as an intervention even in patients with early amyloid pathology — improving glymphatic clearance to partially reverse the accumulation. Sleep apnea — particularly nocturnal hypoxemia — is an especially potent accelerant of Alzheimer’s pathology and responds to CPAP treatment.